Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent

Enzyme replacement therapy (ERT) with recombinant human acid-α-glucosidase (rhGAA) is the only FDA approved therapy for Pompe disease. Without ERT, severely affected individuals (early onset) succumb to the disease within 2 years of life. A spectrum of disease severity and progression exists dependi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nayak, Sushrusha, Doerfler, Phillip A., Porvasnik, Stacy L., Cloutier, Denise D., Khanna, Richie, Valenzano, Ken J., Herzog, Roland W., Byrne, Barry J.
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2014
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4045583/
https://ncbi.nlm.nih.gov/pubmed/24897114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0098336
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires